Alfacell (ACEL) Reports Q1 Loss of $0.06
Alfacell Corporation (Nasdaq: ACEL) reports Q1 loss of $0.06, flat from a loss of $0.06 in the same quarter last year.
Alfacell Corporation, a development stage company, engages in the discovery and development of therapeutic drugs for the treatment of cancer and other pathological conditions primarily in the United States.
Alfacell Corporation, a development stage company, engages in the discovery and development of therapeutic drugs for the treatment of cancer and other pathological conditions primarily in the United States.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Tiffany & Co. (TIF) Misses Q1 EPS Views; Lowers FY12 EPS, Revs Growth Outlook
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
